News & Events

28 03, 2023

NICE recommends life-changing gene therapy for children with ultra-rare genetic disorder

2023-03-28T15:43:47+00:00

A single dose gene therapy designed to correct the underlying genetic defect, eladocagene exuparvovec (also called Upstaza and made by PTC Therapeutics), is infused directly into the brain through a minimally invasive procedure – the first gene therapy to be administered in this way...

NICE recommends life-changing gene therapy for children with ultra-rare genetic disorder2023-03-28T15:43:47+00:00
21 03, 2023

Biodistribution testing of cell and gene therapies

2023-03-21T14:09:40+00:00

Cell and gene therapy drug products represent a rapidly growing field in the development of new treatments for a wide range of diseases. These therapies have the potential to revolutionize medicine by offering cures rather than just managing symptoms. However, with this potential comes unique challenges, particularly with regard to biodistribution testing...

Biodistribution testing of cell and gene therapies2023-03-21T14:09:40+00:00
14 03, 2023

Join Avance Biosciences at Gene Therapy for Rare Disorders – Mar 20-23 – Boston

2023-03-14T14:29:38+00:00

Non-clinical and clinical studies that evaluate pharmacokinetic (ADME) and toxicology characteristics are essential to determine cellular and gene therapy (CGT) product safety and efficacy. Studies on gene vector and transgene biodistribution (BD), gene expression, protein expression, viral shedding, vector integration...

Join Avance Biosciences at Gene Therapy for Rare Disorders – Mar 20-23 – Boston2023-03-14T14:29:38+00:00
7 03, 2023

Gene editing of human stem cells to treat rare disease

2023-03-07T14:14:30+00:00

Gene editing has the potential to transform the lives of patients with previously untreatable conditions, offering hope for a better future. As the technology continues to advance, it is likely that we will see more breakthroughs in this field in the coming years, bringing us closer to a world where rare diseases are...

Gene editing of human stem cells to treat rare disease2023-03-07T14:14:30+00:00
2 03, 2023

Avance Biosciences licenses SeQure Dx’s GUIDE-seq off-target NGS analysis technology

2023-03-02T12:35:29+00:00

Avance Biosciences (Avance), a leading CRO that provides GLP/CGMP-compliant biological testing services that aid drug development and manufacturing, announced today that it has signed a licensing agreement with SeQure Dx, a cutting-edge gene-editing diagnostics company...

Avance Biosciences licenses SeQure Dx’s GUIDE-seq off-target NGS analysis technology2023-03-02T12:35:29+00:00
28 02, 2023

Quality Assurance of E. coli Cell Banks used in Biopharmaceutical Production

2023-02-28T15:29:22+00:00

The use of E. coli cell banks poses some challenges and requires careful attention to quality control and quality assurance to ensure that the cells are of the highest quality and free from contamination or genetic mutations. Testing may include identity, purity, viability, characterization, and stability testing...

Quality Assurance of E. coli Cell Banks used in Biopharmaceutical Production2023-02-28T15:29:22+00:00
23 02, 2023

Join Avance Biosciences at BioProcess International West – Feb 27-Mar 2, 2023!

2023-02-23T15:24:12+00:00

Ensure the Success of Your Biological Drug Development - Avance Provides Assays to Support your Biopharmaceutical Development & Manufacturing - Avance Biosciences is a world-leading CRO specializing in GLP & GMP compliant biological assay development, assay validation, and [...]

Join Avance Biosciences at BioProcess International West – Feb 27-Mar 2, 2023!2023-02-23T15:24:12+00:00
21 02, 2023

Weill Cornell study demonstrates safety of intravenous administration of an AAV8 gene therapy

2023-02-21T17:18:34+00:00

Researchers report on the safety of a gene therapy to treat the common autosomal recessive hereditary disorder alpha 1-antitrypsin (AAT) deficiency in a new article in the peer-reviewed journal Human Gene Therapy. In ATT deficiency, neutrophil proteases destroy the lung parenchyma, the portion of the lungs...

Weill Cornell study demonstrates safety of intravenous administration of an AAV8 gene therapy2023-02-21T17:18:34+00:00
14 02, 2023

Join Avance Biosciences at the mRNA Analytical Development Summit Feb 14-16, 2023!

2023-02-21T17:19:15+00:00

With several years of experience supporting a world-renowned mRNA COVID-19 vaccine company with raw material and drug substance release, Avance Biosciences is well-positioned to provide industry-leading assay design, validation, and sample testing services that advance our clients’ mRNA therapeutic...

Join Avance Biosciences at the mRNA Analytical Development Summit Feb 14-16, 2023!2023-02-21T17:19:15+00:00
7 02, 2023

FDA clears Sana Biotechnology’s CAR T Therapy IND application for patients with B-cell malignancies

2023-02-08T15:33:09+00:00

The goal of the hypoimmune platform is to overcome the immunologic rejection of allogeneic cells, which if true for SC291 may result in longer CAR T cell persistence and a higher rate of durable complete responses for patients with B-cell lymphomas or leukemias. The hypoimmune platform includes disruption of major...

FDA clears Sana Biotechnology’s CAR T Therapy IND application for patients with B-cell malignancies2023-02-08T15:33:09+00:00